Literature DB >> 14656418

How reliable is the history of chickenpox? Varicella serology among children up to 14 years of age.

J Kavaliotis1, S Petridou, D Karabaxoglou.   

Abstract

OBJECTIVES: The aim of this study was to assess the seroprevalence of antibodies to varicella-zoster virus (VZV) in children of northern Greece and to estimate the reliability of varicella history.
METHODS: A serosurvey of 632 children, aged 13 months to 14 years (median 5.2 years), was conducted between April 1999 and July 2001. Serum samples were tested by enzyme-linked immunosorbent assay (ELISA) for IgG antibodies to VZV (IgG Genzyme Virotech GmbH). A history of varicella in these children was obtained from the parents of all these patients. Also, a check of state health cards of the patients was done.
RESULTS: Two hundred and forty-eight (39%) of the children were seropositive for VZV. Two hundred and thirty (36%) of the 632 children claimed to have had previous varicella infection; 87.8% were seropositive, and 12.2% lacked antibodies to VZV. One hundred and seven of the 230 children with a history of varicella had the information about the disease confirmed, as it was reported on their state health card by a pediatrician; 10.2% were seronegative for VZV. Absence of history of varicella was reported in 402 (63.6%) of the 632 children; 88.6% of those were seronegative, and 11.4% were seropositive. The percentage of incorrect negative history ranged from 6% (13-60 months of age) to 48% (120-168 months of age).
CONCLUSIONS: A large proportion of the study group (61%), mainly below 7 years of age, is susceptible to varicella. The positive predictive value of a history of varicella is 87.8%, whereas the negative predictive value of a negative history is 11.4%, which means that there is an 88.6% probability of a negative history being correct. Varicella serology may be reasonable prior to vaccination in children >10 years old with a negative chickenpox history. However, if one excludes cost considerations, it is also reasonable to vaccinate all children, irrespective of serostatus.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14656418     DOI: 10.1016/s1201-9712(03)90106-8

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  6 in total

1.  Presumptive varicella vaccination is warranted in Greek adolescents lacking a history of disease or household exposure.

Authors:  Alexandra Katsafadou; Konstantina Kallergi; George Ferentinos; Theodora Goulioti; Maria Foustoukou; Vassiliki Papaevangelou
Journal:  Eur J Pediatr       Date:  2008-04-05       Impact factor: 3.183

2.  The vascular effects of infection in Pediatric Stroke (VIPS) Study.

Authors:  Heather J Fullerton; Mitchell S V Elkind; A James Barkovich; Carol Glaser; David Glidden; Nancy K Hills; Carlos Leiva-Salinas; Max Wintermark; Gabrielle A Deveber
Journal:  J Child Neurol       Date:  2011-05-25       Impact factor: 1.987

3.  Changes in epidemiological characteristics and sero-prevalence against the varicella zoster virus in school-age children after the introduction of a national immunization program in Japan.

Authors:  Yosuke Yasui; Toshikatsu Mitsui; Fujiyo Arima; Keiko Uchida; Mikako Inokuchi; Mitsuaki Tokumura; Tetsuo Nakayama
Journal:  Hum Vaccin Immunother       Date:  2021-03-02       Impact factor: 3.452

Review 4.  Application of Oral Fluid Assays in Support of Mumps, Rubella and Varicella Control Programs.

Authors:  Peter A C Maple
Journal:  Vaccines (Basel)       Date:  2015-12-09

5.  Estimation of the burden of varicella in Europe before the introduction of universal childhood immunization.

Authors:  Margarita Riera-Montes; Kaatje Bollaerts; Ulrich Heininger; Niel Hens; Giovanni Gabutti; Angel Gil; Bayad Nozad; Grazina Mirinaviciute; Elmira Flem; Audrey Souverain; Thomas Verstraeten; Susanne Hartwig
Journal:  BMC Infect Dis       Date:  2017-05-18       Impact factor: 3.090

6.  Validity of a reported history of chickenpox in targeting varicella vaccination at susceptible adolescents in England.

Authors:  Nigel Field; Gayatri Amirthalingam; Pauline Waight; Nick Andrews; Shamez N Ladhani; Albert Jan van Hoek; Peter A C Maple; Kevin E Brown; Elizabeth Miller
Journal:  Vaccine       Date:  2013-07-16       Impact factor: 3.641

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.